NASDAQ / LIVE COMPANY INTELLIGENCE

Relay Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERRLAY
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / RLAY COVERAGE

What’s moving Relay Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Relay Therapeutics, Inc. (RLAY) expected to beat earnings estimates: Should you buy?

Relay Therapeutics, Inc. (RLAY) expected to beat earnings estimates: Should you buy?

Investors are testing whether Relay Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

The story matters when it changes Relay Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The story matters when it changes Relay Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608

Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608

The story matters when it changes Relay Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple

Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple

Investors are testing whether Relay Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest RLAY filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-05 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-09 · Period 2026-06-09SEC ↗8-KMaterial company eventFiled 2026-05-21 · Period 2026-05-20SEC ↗8-KMaterial company eventFiled 2026-05-19 · Period 2026-05-19SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-09SEC ↗144Official SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Relay Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.